Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

Analysts have given Biogen a total of 11 ratings, with the consensus rating being Outperform. The average one-year price target is $187.27, indicating a potential 46.42% upside.

Biogen (NASDAQ:BIIB) is scheduled to announce Q2 earnings results on Thursday, July 31st, before market open. The consensus EPS Estimate is $3.88 (-3.5% Y/Y) and the consensus Revenue Estimate is ...

Besides Wall Street's top-and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the ...